Previous 10 | Next 10 |
2024-07-11 10:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As investors buy from tech giants like Nvidia, many other compelling opportunities exist for those looking for growth. Driven by innovation, revenue growth, and an enviable market position, eac...
2024-07-09 13:20:20 ET More on Global X Artificial Intelligence & Technology ETF: AIQ: No Real AI Alpha With Heavy Tech Concentration Facing Slowing Growth AIQ: AI Commercialization Will Propel This ETF Higher, Despite Reaching ATH AIQ: Has Generative AI Peaked? ...
2024-07-08 12:30:52 ET Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectab...
2024-07-08 09:07:03 ET Gilead Sciences ( NASDAQ: GILD ) stock has been upgraded to Outperform from Market Perform by Raymond James on positive data from PURPOSE-1 study and expected approval of seladelpar.... Read the full article on Seeking Alpha For further details see...
2024-07-08 07:58:27 ET Ideaya Biosciences ( NASDAQ: IDYA ) shares jumped as much as 23% premarket on Monday after the oncology company reported positive interim data from an expansion dose cohort of a mid-stage trial of IDE397.... Read the full article on Seeking Alpha...
2024-07-04 14:13:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcar...
2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...
2024-07-01 23:57:12 ET Summary Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential r...
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...